Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To estimate the difference in effectiveness between treatment with etanercept 50 mg twice
weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN)
topical agent for 12 weeks in adults with moderate to severe plaque psoriasis.